

**Kasumi-1 Cells | 300226****General information****Description**

The Kasumi-1 cell line was derived from the peripheral blood of a 7-year-old Japanese boy with acute myeloid leukemia (AML), specifically the FAB M2 subtype, during a relapse following bone marrow transplantation. This cell line is a valuable resource for researchers studying hematologic malignancies, especially those involving the t(8;21) chromosomal translocation. This translocation leads to the formation of the AML1-ETO fusion gene, a critical factor in certain subtypes of AML. Kasumi-1 cells thus serve as an essential model for investigating the molecular mechanisms of AML and testing potential therapeutic approaches.

Kasumi-1 cells possess characteristics of both myeloid and macrophage lineages, making them particularly useful for studies on myeloid differentiation. These cells can be induced to differentiate into macrophage-like cells when cultured with phorbol 12-myristate 13-acetate (TPA), providing a robust system for exploring the pathways involved in myeloid lineage commitment and differentiation. This differentiation capacity enhances the utility of Kasumi-1 cells in research focused on both AML biology and broader myeloid cell development processes.

**Organism** Human**Tissue** Blood**Disease** Acute myeloblastic leukemia**Synonyms** KASUMI-1, Kasumi 1, KASUMI1, Kasumi1**Characteristics****Age** 7 years**Gender** Male**Ethnicity** Japanese**Morphology** Round cells showing marked variations in both size and nuclear cytoplasmic ratio.**Cell type** Myeloblast (AML-acute myeloid leukemia)**Growth properties** Suspension**Regulatory Data****Citation** Kasumi-1 (Cytion catalog number 300226)

**Kasumi-1 Cells | 300226****Biosafety level** 1**NCBI\_TaxID** 9606**CellosaurusAccession** CVCL\_0589**Biomolecular Data****Antigen expression** CD4+ (37.1%, coexpressed with CD34 and CD33), CD13+(OKM13), CD15+(LeuM1), CD33+, CD34+(MY10), CD38+(OKT10, 50.1%), CD71+(Nu-TERf), HLA-DR+(OKDR).**Karyotype** t(8,21) chromosome translocation**Handling****Culture Medium** RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO<sub>3</sub> (Cytion article number 820700a)**Doubling time** 40 to 45 hours**Subculturing** Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of  $2 \times 10^5$  cells/ml and keep the cell concentration within the range of  $1 \times 10^5$  to  $1 \times 10^6$  cells/ml for optimal growth.**Split ratio** A ratio of about 1:2 to 1:3 every 3 to 4 days is recommended**Seeding density**  $1 \times 10^5$  cells/ml**Fluid renewal** Add fresh medium (20 to 30% by volume) every 2 to 3 days**Freeze medium** As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.**Quality Control & Molecular Analysis****Sterility**

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

## Kasumi-1 Cells | 300226

### STR profile

**Amelogenin:** x,x  
**CSF1PO:** 10,12  
**D13S317:** 11,13  
**D16S539:** 9,12  
**D5S818:** 9,11  
**D7S820:** 8,11  
**TH01:** 6,9  
**TPOX:** 8,9  
**vWA:** 14  
**D3S1358:** 15,17  
**D21S11:** 30,31  
**D18S51:** 15,16  
**Penta E:** 11  
**Penta D:** 12  
**D8S1179:** 13,14  
**FGA:** 22,24

### HLA alleles

**A\*:** '26:01:01, '26:02:01  
**B\*:** '40:06:01, '48:01:01  
**C\*:** '03:03:01, '08:01:01  
**DRB1\*:** '09:01:02, '14:54:01  
**DQA1\*:** '01:04:01, '03:02:01  
**DQB1\*:** '03:03:02, '05:03:01  
**DPB1\*:** '02:01:02, '02:01:02  
**E:** '01:03:01